A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)

Trial Profile

A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms FINE
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jan 2014 Planned End Date changed from 1 Apr 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 27 Aug 2013 Planned End Date changed from 1 Jan 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top